GlassScriptPhysician profile
Radha Reddy
NPI 1780652073
$1,634.57
in general payments reported to CMS, 2019-2025
32 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $258 · 2021: $156 · 2022: $22.36 · 2024: $78.46 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $185.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $231.29 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $175.63 | 2019-2025 | Evkeeza |
| Amgen INC. | $148.66 | 2019-2021 | |
| Dexcom, INC. | $94.20 | 2019-2020 | |
| Radius Health, INC. | $90.18 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.82 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $68.32 | 2019-2020 | |
| Abbott Laboratories | $66.26 | 2019-2020 | |
| Antares Pharma, INC. | $57.88 | 2019-2021 | |
| Roche Diabetes Care, INC. | $55.99 | 2019 | |
| Sanofi-Aventis U.S. LLC | $53.82 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $50.86 | 2019-2020 | |
| Corcept Therapeutics | $50.81 | 2019-2025 | Korlym |
| Shire North American Group INC | $33.04 | 2019 | |
| Ibsa Pharma INC. | $32.93 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $31.84 | 2019 | |
| Abbvie INC. | $29.47 | 2019 | |
| Insulet Corporation | $29.24 | 2019 | |
| Pfizer INC. | $24.80 | 2019 | |
| Medtronic, INC. | $22.82 | 2021 | |
| Horizon Therapeutics Plc | $22.38 | 2019 | |
| Tandem Diabetes Care, INC. | $22.02 | 2019 | |
| Zealand Pharma US, INC. | $22.00 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.86 | 2021 | |
| Lilly USA, LLC | $19.20 | 2021 | |
| Endo Pharmaceuticals INC. | $18.60 | 2019 | |
| Vivus LLC | $18.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.11 | 2019 | |
| Currax Pharmaceuticals LLC | $14.54 | 2020 | |
| Ascensia Diabetes Care US INC. | $14.17 | 2021 | |
| Lifescan, INC. | $13.54 | 2020 | |
| Amarin Pharma, INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radha Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.